Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Rating of “Reduce” by Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been given an average rating of “Reduce” by the five research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $8.00.

Several brokerages have issued reports on BHC. Weiss Ratings lowered Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th. Barclays dropped their price target on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Finally, Royal Bank Of Canada dropped their price target on Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday, April 27th.

Bausch Health Cos Price Performance

Shares of BHC opened at $4.96 on Wednesday. Bausch Health Cos has a 52-week low of $4.89 and a 52-week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 0.97 and a current ratio of 1.32. The business’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $5.97. The firm has a market cap of $1.85 billion, a PE ratio of -1.53 and a beta of 0.40.

Bausch Health Cos (NYSE:BHC) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.03). Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. On average, equities analysts anticipate that Bausch Health Cos will post 4.08 EPS for the current year.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the transaction, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

A number of institutional investors have recently modified their holdings of BHC. Norges Bank purchased a new stake in Bausch Health Cos in the 4th quarter valued at $25,592,000. MUFG Securities EMEA plc purchased a new stake in Bausch Health Cos in the 2nd quarter valued at $22,644,000. Paulson & CO. Inc. raised its position in Bausch Health Cos by 3.5% in the 4th quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after buying an additional 2,500,000 shares during the last quarter. Royal Bank of Canada raised its position in Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after buying an additional 2,262,894 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Bausch Health Cos by 65.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock valued at $35,748,000 after buying an additional 2,038,813 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.